{
  "docId": "019de077-60e9-755b-a2a9-f474a1c234cc",
  "docSlug": "c7a8fd91214a0cf2ae7cadcb747376a3",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 42,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a timeline-like structure to show the progression from Part A to Part B for two distinct studies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-60e9-755b-a2a9-f474a1c234cc/18",
  "deckHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc",
  "deckJsonHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc.json",
  "deckAnchorHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.735,
        "w": 0.735,
        "x": 0.233,
        "y": 0.188
      },
      "kind": "diagram",
      "text": "Phase 3 Study Design flow from Part A to Part B",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6dd2f5a6-1e41-41ee-abb4-3f52d66f478d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.505,
        "w": 0.185,
        "x": 0.045,
        "y": 0.335
      },
      "kind": "list",
      "text": "Voyage (Study MM120-300) and Panorama (Study MM120-301)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7e4ef2a-40d4-4f3e-ad19-d265dcdd612a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.505,
        "w": 0.06,
        "x": 0.238,
        "y": 0.335
      },
      "kind": "metric",
      "text": "N=100, N=40",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "491c4dfd-1e15-4a3f-ae88-bf845c027a56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.535,
        "x": 0.168,
        "y": 0.928
      },
      "kind": "source-note",
      "text": "1. Studies will employ an adaptive design with interim blinded sample size re-estimation based on nuisance parameters (e.g. patient retention rate, variability of primary outcome measure) to maintain statistical power. Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3clinical trial protocols.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e326d5c-1ea8-4db8-8ad1-22cd646c586f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.052,
        "w": 0.507,
        "x": 0.038,
        "y": 0.048
      },
      "kind": "title",
      "text": "MM120 for GAD | Phase 3 Study Designs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc60b693-115e-4153-8cbb-ae2fb5dd0d33",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "31323dd2-8bc7-42e3-86ea-660ef373a26a",
      "evidence": "Standardized representation of clinical trial phases and arms",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 18,
      "from": 15,
      "beatId": "7f79eae5-2e46-4d31-b209-13e74588623a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Slides 15-18 discuss phase 2 results and market potential",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 16,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "0fbcc614-45f6-482e-a9be-178cb36beb58",
      "evidence": "Slides 16-20 discuss phase 2 results and study designs",
      "position": 1,
      "objective": "Show the pattern of effectiveness in treating GAD",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}